BioCentury
ARTICLE | Company News

Rigel grants Kissei Asian rights to Tavalisse

November 2, 2018 7:53 PM UTC

Rigel granted Kissei exclusive rights to develop and commercialize Tavalisse fostamatinib for all current and future indications in Japan, China, Taiwan and Korea. Rigel said it has the option to co-develop the product in the countries.

Rigel will receive $33 million in cash up front and is eligible for $147 million in development and commercial milestones. Rigel will supply Tavalisse and will receive product transfer price payments in the mid- to upper-twenty percent range based on tiered net sales...